The Top 5 Biosimilar Articles for the Week of April 26

Here are the top 5 biosimilar articles for the week of April 26, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of April 26, 2021.

Number 5: New Brunswick, Canada, has become the third Canadian province to implement a “switching” policy that mandates the use of money-saving biosimilars for patients with inflammatory diseases.

Number 4: The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.

Number 3: The savings from pegfilgrastim biosimilars rapidly add up, according to a study simulation that accounted for hospital costs associated with the on-body injector.

Number 2: Samsung Bioepis has garnered International Forum (iF) Design Award 2021 honors for its biosimilars packaging, which features soft shapes and soothing mono-colors.

Number 1: An ongoing real-world observational study of bevacizumab biosimilar (Mvasi) vs originator (Avastin) has demonstrated comparable safety and effectiveness for a cohort of patients with metastatic colorectal cancer.

To read all of these articles and more, visit centerforbiosimilars.com.